Company news
Lixte Biotechnology Holdings, Inc. news in 2025
Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2025, newest first.
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
December 23, 2025
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
December 18, 2025
LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment
November 26, 2025
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
November 25, 2025
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
October 29, 2025
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
October 16, 2025
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ: LIXT)
September 14, 2025
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
September 10, 2025
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
September 3, 2025
LIXTE Biotechnology Holdings Provides Corporate Update
August 18, 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
August 14, 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
August 14, 2025
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
August 12, 2025
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
July 16, 2025
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
July 9, 2025
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
July 8, 2025
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
July 2, 2025
Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
July 1, 2025
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
March 31, 2025
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
March 27, 2025
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
March 10, 2025
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
February 25, 2025
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 10, 2025
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
February 9, 2025